Breast Cancer Trial, Recruiting NCT06995443 Sponsor: Centre Hospitalier de Valenciennes Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT06995443
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman aged 18 or older
  • You have finished intravenous (drip) chemotherapy for breast cancer (any stage) within the last 12 months
  • You have noticed memory or thinking problems that started during or within 3 months after chemotherapy, confirmed by a specific memory and thinking questionnaire score (confirm with trial site)
  • You are considered suitable for a light therapy treatment called photobiomodulation (confirm with trial site)
  • You can read and understand French well enough to fill in study questionnaires
  • You are willing to sign a written consent form to take part in the trial
  • You have French social security or health insurance coverage
  • You are willing and able to follow all study procedures for the full duration of the trial

Who may not be able to join:

  • You had known memory or thinking problems before starting chemotherapy
  • You have a psychiatric or behavioural condition that would make light therapy sessions unsuitable (confirm with trial site)
  • You have received whole-body light therapy (in a light therapy booth) in the past 12 months or are currently receiving it
  • You have previously had light therapy directed at the brain using a panel or helmet, at any point in the past
  • You are currently taking or have previously taken a chemotherapy drug called capecitabine
  • You are taking part in another study involving a medicine that could affect memory or thinking
  • You suffer from claustrophobia (fear of enclosed spaces)
  • You are unable to read or complete a questionnaire, in the opinion of the study team

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 June 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre Hospitalier de Valenciennes
Registry
ClinicalTrials.gov
Start date
13 June 2025
Est. completion
1 December 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

To compare, among women aged 18 and over who had undergone chemotherapy for breast cancer and had subjective cognitive impairment post-chemotherapy, the rate of those showing improvement in cognitive impairment with or without photobiomodulation (cortica

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov